These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). Ojha R; Singh J; Ojha A; Singh H; Sharma S; Nepali K Expert Opin Ther Pat; 2017 Mar; 27(3):311-345. PubMed ID: 27841045 [TBL] [Abstract][Full Text] [Related]
3. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout. Lü JM; Yao Q; Chen C Biochem Pharmacol; 2013 Nov; 86(9):1328-37. PubMed ID: 23994369 [TBL] [Abstract][Full Text] [Related]
4. Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease? Orhan IE; Deniz FSS Curr Pharm Des; 2021; 27(2):143-158. PubMed ID: 32723252 [TBL] [Abstract][Full Text] [Related]
5. Inhibitors of Xanthine Oxidase: Scaffold Diversity and Structure-Based Drug Design. Luna G; Dolzhenko AV; Mancera RL ChemMedChem; 2019 Apr; 14(7):714-743. PubMed ID: 30740924 [TBL] [Abstract][Full Text] [Related]
6. Pathology, target discovery, and the evolution of XO inhibitors from the first discovery to recent advances (2020-2023). Kumar N; Kaur K; Kaur N; Singh E; Bedi PMS Bioorg Chem; 2024 Feb; 143():107042. PubMed ID: 38118298 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of hydroxychalcones as multifunctional non-purine xanthine oxidase inhibitors for the treatment of hyperuricemia. Xie Z; Luo X; Zou Z; Zhang X; Huang F; Li R; Liao S; Liu Y Bioorg Med Chem Lett; 2017 Aug; 27(15):3602-3606. PubMed ID: 28655421 [TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen. Ogura J; Kuwayama K; Sasaki S; Kaneko C; Koizumi T; Yabe K; Tsujimoto T; Takeno R; Takaya A; Kobayashi M; Yamaguchi H; Iseki K Biochem Pharmacol; 2015 Sep; 97(1):89-98. PubMed ID: 26119820 [TBL] [Abstract][Full Text] [Related]
9. Mehmood A; Rehman AU; Ishaq M; Zhao L; Li J; Usman M; Zhao L; Rehman A; Zad OD; Wang C Comb Chem High Throughput Screen; 2020; 23(9):917-930. PubMed ID: 32342806 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors. Zhang B; Duan Y; Yang Y; Mao Q; Lin F; Gao J; Dai X; Zhang P; Li Q; Li J; Dai R; Wang S Eur J Med Chem; 2022 Jan; 227():113928. PubMed ID: 34688012 [TBL] [Abstract][Full Text] [Related]
15. Effects of extracts from Corylopsis coreana Uyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia. Yoon IS; Park DH; Ki SH; Cho SS J Pharm Pharmacol; 2016 Dec; 68(12):1597-1603. PubMed ID: 27696407 [TBL] [Abstract][Full Text] [Related]
17. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Bove M; Cicero AF; Veronesi M; Borghi C Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818 [TBL] [Abstract][Full Text] [Related]
18. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Schumacher HR Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578 [TBL] [Abstract][Full Text] [Related]
19. Effects of lobetyolin on xanthine oxidase activity Yoon IS; Cho SS Nat Prod Res; 2021 May; 35(10):1667-1670. PubMed ID: 31140315 [TBL] [Abstract][Full Text] [Related]
20. Discovery of 2-phenylthiazole-4-carboxylic acid, a novel and potent scaffold as xanthine oxidase inhibitors. Xu X; Deng L; Nie L; Chen Y; Liu Y; Xie R; Li Z Bioorg Med Chem Lett; 2019 Feb; 29(4):525-528. PubMed ID: 30630716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]